Human embryonic stem cell lines
Description:

Relicell hES1, Relicell hES2 and Relicell hES3 Human Embryonic Stem Cell Lines

Product Overview

Relicell hES1, Relicell hES2 and Relicell hES3 are pluripotent human embryonic stem cell lines capable of differentiation to representatives of the three primary germ layers. The cell line satisfies the criteria that characterize pluripotent stem cells: They express high levels of cell surface markers (such as SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81), transcription factor Oct4, alkaline phosphatase and telomerase. All the Relicell hESC lines have a stable and normal karyotype.

These cell lines has been screened and found negative for Hepatitis B and C, human immunodeficiency virus 1 and 2, Herpes Simplex Virus 1 and 2, Cytomegalovirus. In addition, the hESC cultures are also regularly tested for the absence of mycoplasma.

The cells are provided at passage 10-15, which is ideal for maximizing the stable lifespan of the cell line. The early passage Relicell hESC lines provide extended research time in a stable, pluripotent state. The Relicell hES cell lines grow as well defined colonies, with compact cells displaying high nuclear to cytoplasmic ratios and prominent nucleoli.

Source:

All hES cell lines supplied by RLS are derived from supernumerary embryos created for the purpose of assisted reproduction and donated with written informed consent from the patients. The research and handling of hES cells is based on careful ethical consideration and approved by Institutional Committee for Stem Cell Research and Therapy.

When procuring hES cell lines from RLS, you will receive a whole service package consisting of extensive protocols for the culture, freezing and thawing procedures as well as characterization documentation along with highly qualified technical support.

Pack Size:

1 vial containing ~ 50 colonies.

Use Restrictions:

These cells are distributed for research purpose only.

References:

Mandal,A ., Tipnis, S., Pal ,R., Ravindran, G., Bose, B. , Patki , A., Rao, M., Khanna, A. (2006) Characterization and in vitro differentiation potential of a new human embryonic stem cell line, ReliCellhES1. Differentiation 74:110

Bibikova M, Chudin E, Wu B, Zhou L, Garcia EW, Liu Y, Shin S, Plaia TW, Auerbach J, Arking D, Gonzalez R, Crook J, Davidson B, Schulz TC, Robins A, Khanna A, Sartipy P, Hyllner J, Vanguri P, Bhonsale SS, Smith AK, Chakravarti A, Maitra A, Rao M, Barker DL, Loring JF, Fan JB (2006) Human embryonic stem cells have a unique epigenetic signature. Genome Research 16(9): 10751083.

Pal R., Mandal A, Rao HS, Rao, M, Khanna, A. (2007) A panel of tests to standardize the characterization of human embryonic stem cells. Regenerative Medicine 2(2): 179-192.

Pal R, Khanna A. (2007) Similar pattern in cardiac differentiation of human embryonic stem cell lines, BG01V and ReliCellhES1, under low serum concentration supplemented with bone morphogenetic protein-2. Differentiation 75(2):112-22.

Mehta A, Konala VB, Khanna A, Majumdar AS. (2008) Assessment of drug induced developmental toxicity using human embryonic stem cells. Cell Biol Int. 32(11):1412-24.

Geeta R, Ramnath RL, Rao HS, Chandra V (2008 ) One year survival and significant reversal of motor deficits in parkinsonian rats transplanted with hESC derived dopaminergic neurons. . Biochem Biophys Res Commun. 373(2):258-64.

Mandal A, Bhowmik S, Patki A, Viswanathan C, Majumdar AS (2010) Derivation, characterization, and gene expression profile of two new human ES cell lines from India Stem Cell Research,3:173-87

Mehta A, Mathew S, Viswanathan C, Majumdar AS (2010) Intrinsic properties and external factors determine the differentiation bias of human embryonic stem cell lines., Cell Biol Int. 34(10):1021-31.

Human umbilical cord blood derived stem cells (CD34+ cells)
Description:

Product Overview:


Introduction:
Umbilical cord blood (UCB) has gained a lot of importance since the first successful hematopoietic stem cell transplant. Hematopoietic stem cells (HSCs) are identified by the expression of cell surface marker CD34, and hence they are termed as CD34+ stem cells. The CD34+ cells are characterized by the dual ability to self renew and reconstitute and differentiate into progenitors of all the mature blood lineages. The CD34+ HSCs resemble lymphocytes. They are rounded and shows low cytoplasm-to-nucleus ratio. These cells are cultured as non-adherent suspension culture. We isolate the CD34+ HSCs from UCB, expand them in vitro and characterize them for their phenotypic expression. They are then cryopreserved till further use.

Source:

Umbilical cord blood is collected from healthy voluntary donors after obtaining necessary consent as per the recommendations of the institutional ethics committee. The maternal blood from whom the cord blood is obtained, after due consenting is screened for HIV I and II and HBsAg, HCV antibody, CMV IgG and IgM and syphilis IgG/IgM. The final product washes are tested for Sterility, Endotoxin and Mycoplasma.

Pack Size:

1 vial containing 5 million CD34+ cells

Use Restrictions:

These cells are distributed for research purpose only.

When acquiring CD34+ cells from RLS you will receive a whole service package consisting of extensive protocols for culture, freezing and thawing procedures as well as characterization documentation along with highly qualified technical support.

References :

  • Shetty P, Bharucha K and Tanavde V,. (2007) Human umbilical cord blood serum can replace fetal bovine serum in the culture of mesenchymal stem cells. Cell Biology International 31, 293-298.


  • Shetty P, Cooper K, Viswanathan C. (2010) Comparison of proliferative and multilineage differentiation potentials of cord matrix cord blood and bone marrow derived mesenchymal stem cells. Asian J Transf Sci 4: 1424.


  • Tipnis S, Viswanathan C. (2010) Umbilical cord matrix derived mesenchymal stem cells can change the cord transplant scenario. Intl J Stem Cells 3 (2),: 103-118.


  • Cooper K, Sen Majumdar A, Viswanathan C. (2010) Derivation, expansion and characterization of clinical grade mesenchymal stem cells from umbilical cord matrix using cord blood serum. Intl J Stem Cells ,3 (2): 119-128.,

Human umbilical cord derived mesenchymal stem cells (UCMSCs)

Product Overview

Introduction:
Mesenchymal stem cells (MSCs), derived from umbilical cord (UCMSC). are multipotent, spindle- like adherent cells capable of self-renewal and can differentiate in vitro to bone, cartilage and adipose tissues. Phenotypic characterization studies of MSCs have demonstrated that these cells express CD73, CD105, CD90, CD29, CD44 cell surface antigens and are negative for CD34, CD45, CD31, CD14, HLA- Class II antigens and von Willebrand Factor (v WF). In vitro differentiation studies have demonstrated that MSCs can trans-differentiate into other lineages including ectoderm (neurons) and endoderm (hepatocytes, pancreatic). In addition to their self-renewing and differentiation abilities, MSCs possess unique immunological properties. The expanded UCMSCs exhibit normal karyotype even at higher passages (P12).

Source:

Umbilical cords are collected from healthy donors after obtaining necessary consent as per the recommendations of the institutional ethics committee. The maternal blood from whom the cord is obtained after due consenting is screened for HIV I and II antibodies and HBsAg, HCV antibody, CMV IgG and IgM and syphilis IgG/IgM. The final product washes are tested for Sterility, Endotoxin and Mycoplasma.

Pack Size:

1 vial containing 5 million UCMSCs

Use Restrictions:

These cells are distributed for research purpose only.

When acquiring UCMSCs from RLS, you will receive a whole service package consisting of extensive protocols for the culture, freezing and thawing procedures as well as characterization documentation along with qualified technical support.

References :

  • Shetty P, Cooper K, Viswanathan C. (2010) Comparison of proliferative and multilineage differentiation potentials of cord matrix cord blood and bone marrow derived mesenchymal stem cells. Asian J Transf Sci; 4: 1424.


  • Tipnis S, Viswanathan C, SenMajumdar A. (2010) Immunosuppressive properties of human umbilical cord derived mesenchymal stem cells: Role of B7-H1 and IDO. Immunology and Cell Biology; 88: 795 - 806


  • Tipnis S, Viswanathan C. (2010) Umbilical cord matrix derived mesenchymal stem cells can change the cord transplant scenario. Intl J Stem Cells; 3 (2): 103-118.


  • Cooper K, Sen Majumdar A, Viswanathan C. (2010) Derivation, expansion and characterization of clinical grade mesenchymal stem cells from umbilical cord matrix using cord blood serum. Intl J Stem Cells; 3 (2): 119-128.


  • Cooper K, Viswanathan C. (2011) Establishment of a Mesenchymal Stem Cell Bank.. Stem Cell international (In press).

For further details , Please contact : RLS_regenmed@relbio.com